Truist Securities Maintains Buy on Sabra Health Care REIT, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Buy rating on Sabra Health Care REIT and increased its price target from $16 to $18, indicating confidence in the company's future performance.
September 04, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reaffirmed its Buy rating on Sabra Health Care REIT and increased the price target from $16 to $18, suggesting a positive outlook for the stock.
The increase in price target from $16 to $18 by Truist Securities indicates a positive outlook for Sabra Health Care REIT. The Buy rating suggests that the analyst expects the stock to perform well, which could lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100